Top

Published in:

01-02-2012 | Letter to the Editors

A TASH experience: post-infarction myocardial oedema necessitating the support of ECMO and occurrence of significant mitral regurgitation

Authors: D. Basic, H. Möllmann, M. A. Haas, A. Rolf, A. Jovanovic, Christoph Liebetrau, Sebastian Szardien, J. Leick, Oliver Dörr, A. Skwara, T. Walther, C. W. Hamm, H. M. Nef

Published in: Clinical Research in Cardiology | Issue 2/2012

Excerpt

Sirs: …

Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer Iii WH, Spirito P, Ten Cate FJ (2003) American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy☆a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the european society of cardiology committee for practice guidelines. J Am Coll Cardiol 42(9):1687–1713. doi:10.1016/s0735-1097(03)00941-0 PubMedCrossRef

Elliott P, McKenna W (2004) Hypertrophic cardiomyopathy. Lancet 363(9424):1881–1891. doi:10.1016/s0140-6736(04)16358-7 PubMedCrossRef

Fifer MA, Vlahakes GJ (2008) Management of symptoms in hypertrophic cardiomyopathy. Circulation 117(3):429–439. doi:10.1161/CIRCULATIONAHA.107.694158 PubMedCrossRef

Maron BJ (2007) Controversies in cardiovascular medicine: surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 116(2):196–206. doi:10.1161/CIRCULATIONAHA.107.691378 (discussion 206)PubMedCrossRef

Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346(8969):211–214PubMedCrossRef

Rigopoulos AG, Seggewiss H (2010) A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J 75(1):28–37PubMedCrossRef

Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boekstegers P, Neuhaus L, Seipel L, Horstkotte D (2005) Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German cardiac society. Z Kardiol 94(8):516–523. doi:10.1007/s00392-005-0256-8 PubMedCrossRef

Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287(10):1308–1320PubMedCrossRef

Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR (2010) Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol 55(8):823–834. doi:10.1016/j.jacc.2009.09.047 PubMedCrossRef

10.

Maron BJ (2000) Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 355(9202):425–426. doi:10.1016/S0140-6736(00)82005-X PubMedCrossRef

11.

Fifer MA (2007) Controversies in cardiovascular medicine: most fully informed patients choose septal ablation over septal myectomy. Circulation 116(2):207–216. doi:10.1161/CIRCULATIONAHA.107.688135 (discussion 216)PubMedCrossRef

12.

Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM (2003) Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 42(2):296–300PubMedCrossRef

13.

Angelini P (2007) The “1st septal unit” in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience. Tex Heart Inst J 34(3):336–346PubMed

14.

Aqel RA, Hage FG, Zohgbi GJ, Tabereaux PB, Lawson D, Heo J, Perry G, Epstein AE, Dell’ Italia LJ, Iskandrian AE (2008) Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricular outflow pressure gradients. Am J Cardiol 101(9):1328–1333. doi:10.1016/j.amjcard.2007.12.042 PubMedCrossRef

15.

Yoerger DM, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA (2006) Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 97(10):1511–1514. doi:10.1016/j.amjcard.2005.12.040 PubMedCrossRef

16.

Bartlett RH (2005) Extracorporeal life support: history and new directions. ASAIO J 51(5):487–489PubMedCrossRef

17.

Robinson B, Eshaghpour E, Ewing S, Baumgart S (1998) Hypertrophic obstructive cardiomyopathy in an infant of a diabtic mother. ASAIO J 44:845–847PubMedCrossRef

Title: A TASH experience: post-infarction myocardial oedema necessitating the support of ECMO and occurrence of significant mitral regurgitation
Authors: D. Basic
H. Möllmann
M. A. Haas
A. Rolf
A. Jovanovic
Christoph Liebetrau
Sebastian Szardien
J. Leick
Oliver Dörr
A. Skwara
T. Walther
C. W. Hamm
H. M. Nef
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Clinical Research in Cardiology / Issue 2/2012
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-011-0396-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

A TASH experience: post-infarction myocardial oedema necessitating the support of ECMO and occurrence of significant mitral regurgitation

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2012

Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement

PCI ad hoc or PCI at an interval: a risk calculation

Prognostic utility of T-wave alternans in a real-world population of patients with left ventricular dysfunction: the PREVENT-SCD study

Caval flow reflects Fontan hemodynamics: quantification by magnetic resonance imaging

Remote monitoring of heart failure patients using implantable cardiac pacing devices and external sensors: results of the Insight-HF study

Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page